1\) Treatment in Peking University People's Hospital for radical resection of breast cancer and had hospitalization records;
2\) Postoperative pathology confirmed invasive breast cancer, and the pathological stage was T1c, N0, HER2 positive, with other high-risk factors (G3, or hormone receptor negative); Or the pathological stage is T2, N0, and there are no high-risk factors (G3, or hormone receptor negative);
3)Signed an agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital.
You may not be if
1\) Lack of clinical pathological data (such as imaging data, pathological data);
2\) Preoperative neoadjuvant therapy;
3\) Patients with metastatic breast cancer or bilateral breast cancer;
4\) Failed to undergo curative surgery.
Clareo Health | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
